

Opioid Products – Virginia Prior Authorization Request Form

Please complete this <u>entire</u> form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Member Information			Prescriber Information					
Member Name:			Provider Name	:				
Member ID:			NPI#:	NPI#: Specialty:				
Date Of Birth:			Office Phone:		.1			
Street Address:			Office Fax:	Office Fax:				
City:	State:	ZIP Code:	Office Street Ad	Office Street Address:				
Phone:	Allergies	S:	City:	State:		ZIP Code:		
Is the requested medic	cation: New	or □ Continua	tion of Therapy? If c	ontinuation, lis	st start da	ate:		
Is this patient currentl	y hospitalized	? □ Yes □ No	o If recently discharg	ged, list discha	arge date	:		
Is this member pregna	ınt? □ Yes □ I	No If yes, who	at is this member's d	ue date?				
		Medi	cation Informatio	n				
Medication:					Strength:			
Directions for use:					Quantity:			
Medication Administered		istered □ Ph	ysician's Office	ther:	<u>I</u>			
			nical Information					
What is the nationt's	liannasia fart							
What is the patient's o	ilagilosis loi t	ne medication	being requested?					
ICD-10 Code(s):								
Are there any supporting	laboratory or to	est results relate	ed to the patient's diagr	nosis? (Please s	pecify or pr	ovide documentation)		
	Prev	ious Medica	tion Trials / Cont	raindication	ıs			
Pleas			ww.uhcprovider.com f			natives		
What medication(s) does the patient have a history of <u>failure</u> to? (Please specify <u>ALL</u> medication(s)/strengths tried, directions, length of trial, and reason for discontinuation of each medication)								
What medication(s) does	the patient hav	ve a <u>contraindica</u>	ation or intolerance to?	Please specify	ALL medic	cation(s) with the		
associated contraindication	n to or specific is	sues resulting in	intolerance to each med	lication)		. ,		
	Additio	nal informatior	n that may be importa	ant for this rev	iew			



Opioid Products – Virginia Prior Authorization Request Form

Clinical and Drug Specific Information ALL REQUESTS Does the patient meet any of the following conditions or care instances? ((If yes, check which applies) Long term care (LTC) facility Active cancer related pain Long term care (LTC) facility Palliative care (treatment of symptoms associated with life intigilinesses) Palliative care (treatment of symptoms associated with life intigilinesses) Sickle cell disease Severe post-operative pain Severe post-operat	Patient First name:		Patient Last n	ame:	Patient DOB:		
Ves No Does the patient meet any of the following conditions or care instances? (ff yes, check which applies) Active cancer related pain		Cli	nical and Dru	n Specific Informat	ion		
Does the patient meet any of the following conditions or care instances? (If yes, check which applies) Active cancer related pain Breakthrough cancer pain Chronic, moderate to severe pain chronic masses and		0					
Yes No		Does the patient meet			e instances?		
Yes							
Chronic, moderate to severe pain associated with life limiting illnesses) Hospice care or end of life care Severe post-operative pain Sickle cell disease Sickle		□ Active cancer relate	ed pain	Ε	□ Long term care (LTC) facility		
Chronic, moderate to severe pain associated with life limiting illnesses) Severe post-operative pain Severe pain Severe post-operative pain Severe p	□ Yes □ No	□ Breakthrough canc	er pain				
In remission from cancer and the prescriber is safely weaning patient off of opioids with a tapering plan What is the patient's active daily morphine milligram equivalents (MME) from the prescription monitoring program (PMP) website? What is the date of the patient's last opioid prescription from the PMP website? What is the date of the patient's last benzodiazepine prescription from the PMP website? What is the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level prior to initiating treatment with the requested medication? Yes	- 103 - NO		•				
What is the patient's active daily morphine milligram equivalents (MME) from the prescription monitoring program (PMP) website?		•			·		
What is the patient's active daily morphine milligram equivalents (MME) from the prescription monitoring program (PMP) website?				our bor to during	Sickle cell disease		
what is the date of the patient's last opioid prescription from the PMP website? What is the date of the patient's last benzodiazepine prescription from the PMP website? What is the date of the patient's last benzodiazepine prescription from the PMP website? Has the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level prior to initiating treatment with the requested medication? Has the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level at least every 3 months for the first year of treatment and at least every 6 months thereafter to ensure adherence? Yes No Does the prescriber attest that a treatment plan with goals that addresses benefits and harm has been established with the patient? Is the patient established on pain therapy with the requested medication for cancer-related pain or palliative care pain, AND the medication is not a new regimen for treatment of cancer-related pain or palliative care pain? If yes, list date regimen was started: Yes No Does the patient require continuous around-the-clock analgesia therapy? If the patient is a woman between the ages of 18 to 45 years of age, has the provider counseled the patient on becoming pregnant while receiving opioids, including the risk of Neonatal Opioid Withdrawal Syndrome and offered access to contraceptive services when necessary? Has naloxone been prescribed for patients with any of the following risk factors? (If yes, check which applies. If no, list reason below) Concomitant antihistamines Concomitant tricyclic antidepressants Concomitant antipsychotics Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) Concomitant gabapentin Substance use disorder					and (MARE) for an the annual of the		
What is the date of the patient's last benzodiazepine prescription from the PMP website? Yes No					ents (MME) from the prescription		
Yes No		What is the date of the	e patient's last o	pioid prescription from	the PMP website?		
Yes No Prior to initiating treatment with the requested medication? Yes No Has the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level at least every 3 months for the first year of treatment and at least every 6 months thereafter to ensure adherence? Yes No Does the prescriber attest that a treatment plan with goals that addresses benefits and harm has been established with the patient? Yes No Is the patient established on pain therapy with the requested medication for cancer-related pain or palliative care pain, AND the medication is not a new regimen for treatment of cancer-related pain or palliative care pain? If yes, list date regimen was started: Yes No Does the patient require continuous around-the-clock analgesia therapy? Yes No If the patient is a woman between the ages of 18 to 45 years of age, has the provider counseled the patient on becoming pregnant while receiving opioids, including the risk of Neonatal Opioid Withdrawal Syndrome and offered access to contraceptive services when necessary? Has naloxone been prescribed for patients with any of the following risk factors? (If yes, check which applies. If no, list reason below) Concomitant antihistamines Concomitant tricyclic antidepressants Concomitant antipsychotics Concomitant tricyclic antidepressants Concomitant antipsychotics Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) Concomitant gabapentin Substance use disorder Concomitant pregabalin		What is the date of the	e patient's last b	enzodiazepine prescrip	otion from the PMP website?		
Yes No least every 3 months for the first year of treatment and at least every 6 months thereafter to ensure adherence? Yes No Does the prescriber attest that a treatment plan with goals that addresses benefits and harm has been established with the patient? Yes No Is the patient established on pain therapy with the requested medication for cancer-related pain or palliative care pain, AND the medication is not a new regimen for treatment of cancer-related pain or palliative care pain? Yes No Does the patient require continuous around-the-clock analgesia therapy? Yes No If the patient is a woman between the ages of 18 to 45 years of age, has the provider counseled the patient on becoming pregnant while receiving opioids, including the risk of Neonatal Opioid Withdrawal Syndrome and offered access to contraceptive services when necessary? Has naloxone been prescribed for patients with any of the following risk factors? (If yes, check which applies. If no, list reason below) Concomitant antihistamines Concomitant tricyclic antidepressants Concomitant antihistamines Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) Concomitant gabapentin Substance use disorder Concomitant pregabalin	□ Yes □ No				n (UDS) or serum medication level		
been established with the patient? Is the patient established on pain therapy with the requested medication for cancer-related pain or palliative care pain, AND the medication is not a new regimen for treatment of cancer-related pain or palliative care pain? If yes, list date regimen was started: Does the patient require continuous around-the-clock analgesia therapy? If the patient is a woman between the ages of 18 to 45 years of age, has the provider counseled the patient on becoming pregnant while receiving opioids, including the risk of Neonatal Opioid Withdrawal Syndrome and offered access to contraceptive services when necessary? Has naloxone been prescribed for patients with any of the following risk factors? (If yes, check which applies. If no, list reason below) Concomitant antihistamines Concomitant tricyclic antidepressants Concomitant antipsychotics Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) Concomitant gabapentin Substance use disorder Concomitant pregabalin	□ Yes □ No	least every 3 months					
palliative care pain, AND the medication is not a new regimen for treatment of cancer-related pain or palliative care pain? Yes No Does the patient require continuous around-the-clock analgesia therapy? Yes No Not Applicable If the patient is a woman between the ages of 18 to 45 years of age, has the provider counseled the patient on becoming pregnant while receiving opioids, including the risk of Neonatal Opioid Withdrawal Syndrome and offered access to contraceptive services when necessary? Has naloxone been prescribed for patients with any of the following risk factors? (If yes, check which applies. If no, list reason below) Concomitant antihistamines Concomitant tricyclic antidepressants Concomitant antipsychotics Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) Concomitant gabapentin Substance use disorder Concomitant pregabalin Concomitant pregabalin Concomitant pregabalin Concomitant pregabalin Concomit	□ Yes □ No						
Yes No Not Applicable If the patient is a woman between the ages of 18 to 45 years of age, has the provider counseled the patient on becoming pregnant while receiving opioids, including the risk of Neonatal Opioid Withdrawal Syndrome and offered access to contraceptive services when necessary? Has naloxone been prescribed for patients with any of the following risk factors? (If yes, check which applies. If no, list reason below) Concomitant antihistamines Concomitant tricyclic antidepressants Concomitant antipsychotics Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) Concomitant benzodiazepine use Doses in excess of 50 MME/day Concomitant gabapentin Substance use disorder Concomitant pregabalin	□ Yes □ No	palliative care pain, A or palliative care pain	ND the medication?				
patient on becoming pregnant while receiving opioids, including the risk of Neonatal Opioid Withdrawal Syndrome and offered access to contraceptive services when necessary? Has naloxone been prescribed for patients with any of the following risk factors? (If yes, check which applies. If no, list reason below) Concomitant antihistamines Concomitant tricyclic antidepressants Concomitant antipsychotics Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) Concomitant benzodiazepine use Doses in excess of 50 MME/day Concomitant gabapentin Substance use disorder Concomitant pregabalin	□ Yes □ No	Does the patient requi	ire continuous a	round-the-clock analge	esia therapy?		
(If yes, check which applies. If no, list reason below) □ Concomitant antihistamines □ Concomitant tricyclic antidepressants □ Concomitant antipsychotics □ Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) □ Concomitant benzodiazepine use □ Doses in excess of 50 MME/day □ Concomitant gabapentin □ Substance use disorder □ Concomitant pregabalin		patient on becoming p	oregnant while re	eceiving opioids, inclu	ding the risk of Neonatal Opioid		
□ Concomitant antihistamines □ Concomitant tricyclic antidepressants □ Concomitant tricyclic antidepressants □ Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) □ Concomitant benzodiazepine use □ Concomitant gabapentin □ Concomitant pregabalin □ Concomitant pregabalin		Has naloxone been pr	escribed for pati	ents with any of the fo	llowing risk factors?		
□ Yes □ No □ Concomitant antipsychotics □ Concomitant "Z" drugs (eszopiclone, zolpidem, or zaleplon) □ Concomitant benzodiazepine use □ Doses in excess of 50 MME/day □ Concomitant gabapentin □ Substance use disorder		(If yes, check which app	olies. If no, list rea	ison below)			
□ Yes □ No □ Concomitant benzodiazepine use □ Doses in excess of 50 MME/day □ Concomitant gabapentin □ Substance use disorder □ Concomitant pregabalin	□ Yes □ No			•	•		
☐ Concomitant gabapentin ☐ Substance use disorder ☐ Concomitant pregabalin		·					
□ Concomitant pregabalin			•		-		
				- Cabstance ase disort			
		. •					



Opioid Products – Virginia Prior Authorization Request Form

Patient First name:		Patient Last name:		Patient DOB:		
		-	s Medication 7	Frials/Contraindications" section on first		
□ Yes □ No	page) □ Baclofen □ Capsaicin gel □ Cognitive behaviora □ Duloxetine □ Gabapentin	☐ NSAIDs I therapy ☐ Physica	, ,	ants		
	Requests for short-ac					
□ Yes □ No	Does the patient have a history of contraindication, drug-drug interaction with, or toxic side effects that cause immediate or long-term damage from at least TWO preferred products? (If yes, complete "Previous Medication Trials/Contraindications" section on first page)					
□ Yes □ No	effects that cause imm	a history of contraindicati nediate or long-term dama	ge from any	g interaction with, or toxic side of the following? Frials/Contraindications" section on first		
	□ Butrans (buprenorphine) transdermal □ Morphine sulfate controlled release tablets (specifically generic MS Contin) □ Preferred fentanyl transdermal					
	Requests for Tramado	ol 100mg tablets:				
□ Yes □ No	Is there rationale for needing to use the 100 mg tramadol tablet instead of two 50 mg tramadol tablets? If yes, document rationale:					
	Requests for Qdolo:					
Does the patient meet any of the following? (If yes, check all that apply) □ Patient has a history of failure, contraindication or intolerance to a trial of tramadol 50 mg tablets (If yes, complete "Previous Medication Trials/Contraindications" section on first page) □ Patient is unable to swallow a solid dosage form □ Patient utilizes a feeding tube for medication administration			to a trial of tramadol 50 mg tablets			
EXCEEDING 90 MME CUMULATIVE THRESHOLD						
□ Yes □ No	That they will bHave reviewedAcknowledge th	-	oid therapy lo ne (BOM) Reg high dose opi	ng term gulations for Opioid Prescribing oid therapy including fatal overdose		
□ Yes □ No	Has the prescriber pre	escribed naloxone?				

Provider Signature: _	Date:

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.